Orforglipron

ATC — · 3 markets · 13 records

Orforglipron 3 markets · 13 records Forms

US 6 records · 6 strengths

17.2 mgtabletFOUNDAYO also in GB
14.5 mgtabletFOUNDAYO also in GB
9 mgtabletFOUNDAYO also in GB
5.5 mgtabletFOUNDAYO also in GB
2.5 mgtabletFOUNDAYO also in GB
0.8 mgtabletFOUNDAYO

GB 6 records · 6 strengths

17.2 mgtabletFOUNDAYO also in US
14.5 mgtabletFOUNDAYO also in US
9 mgtabletFOUNDAYO also in US
5.5 mgtabletFOUNDAYO also in US
2.5 mgtabletFOUNDAYO also in US

Records without a stated strength · 1 FOUNDAYO

MX 1 records · 1 strengths

Records without a stated strength · 1 FOUNDAYZ

Side-by-side table

Strength / form / release	US	GB	MX
17.2 mg tablet	FOUNDAYO	FOUNDAYO	not recorded
14.5 mg tablet	FOUNDAYO	FOUNDAYO	not recorded
9 mg tablet	FOUNDAYO	FOUNDAYO	not recorded
5.5 mg tablet	FOUNDAYO	FOUNDAYO	not recorded
2.5 mg tablet	FOUNDAYO	FOUNDAYO	not recorded
0.8 mg tablet	FOUNDAYO	not recorded	not recorded
not disclosed tablet	not recorded	FOUNDAYO	FOUNDAYZ

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.